Dapagliflozin for mild to moderate ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests whether dapagliflozin (a medicine often used for diabetes) can help calm inflammation in people with mild to moderate ulcerative colitis. It's a new way of treating UC by working with the body's natural cleanup process.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have mild or moderate ulcerative colitis (UC), confirmed by a colonoscopy.
- You are not currently breastfeeding, and you do not have serious liver or kidney problems.
- You do not have colorectal cancer or severe UC.
- You are not taking steroids (by mouth or rectum), immune-suppressing drugs, or biologic therapies for your UC.
- You do not have an alcohol or drug addiction, and you are not allergic to dapagliflozin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding metformin to usual care can help people with mild to moderate ulcerative colitis. The goal is to see if it improves symptoms and disease control compared with standard therapy alone.
This early trial studies whether empagliflozin can improve ulcerative colitis symptoms and is safe for people with mild to moderate disease. If it works, it may reduce ongoing colon inflammation and help people feel better.
This trial tests whether adding alpha lipoic acid (an antioxidant) to your usual mesalamine treatment helps control mild to moderate ulcerative colitis. It is for people newly diagnosed and not on other UC treatments.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests whether dapagliflozin, a diabetes medication, can safely increase red blood cell counts and reduce the need for transfusions in patients with lower-risk myelodysplastic syndromes (a blood disorder where the bone marrow doesn't make enough healthy blood cells). The goal is to help patients with anemia feel less tired and avoid frequent blood transfusions.
This study tests if a once-daily medication called dapagliflozin (Forxiga) can reduce inflammation and improve iron use and red blood cell production in people with both type 2 diabetes and chronic kidney disease. It may help protect your kidneys and overall health.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.